Tandem Diabetes Care (TNDM) EPS (Weighted Average and Diluted) Growth (1y) (2019 - 2026)
Tandem Diabetes Care (TNDM) EPS (Weighted Average and Diluted) Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | -19.74% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 14.20% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | -11.88% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 100.00% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | 8.20% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | -30.89% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 88.89% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 47.37% |
| 10 | Tandem Diabetes Care | 1.13 Bn | 557.61 Mn | 136.79 Mn | 84.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.77% |
| Dec 31, 2025 | -200.00% |
| Sep 30, 2025 | 11.43% |
| Jun 30, 2025 | -65.96% |
| Mar 31, 2025 | -203.08% |
| Dec 31, 2024 | 102.17% |
| Sep 30, 2024 | 31.37% |
| Jun 30, 2024 | 14.55% |
| Mar 31, 2024 | 66.15% |
| Dec 31, 2023 | -84.00% |
| Sep 30, 2023 | 32.89% |
| Jun 30, 2023 | -129.17% |
| Mar 31, 2023 | -734.78% |
| Dec 31, 2022 | -256.25% |
| Sep 30, 2022 | -944.44% |
| Jun 30, 2022 | -500.00% |
| Mar 31, 2022 | -187.50% |
| Dec 31, 2021 | -27.27% |
| Sep 30, 2021 | 160.00% |
| Jun 30, 2021 | 113.33% |